EMA Authorised: Synagis (palivizumab) — AstraZeneca AB

View source ↗

Summary

The EMA authorised Synagis (palivizumab) for respiratory syncytial virus infections, with AstraZeneca AB as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Status: Authorised. Therapeutic area: Respiratory Syncytial Virus Infections. MAH: AstraZeneca AB. Decision date: 14/09/2023